Alison Motsinger-Reif, Ph.D.

Senior Investigator

Biostatistics & Computational Biology Branch


A332 David P Rall Building
111 Tw Alexander Dr
Research Triangle Park, NC 27709


Research Topics

My lab members and I develop and extend methods that detect gene-gene and gene-environment interactions. These methods include Multifactor Dimensionality Reduction and Grammatical Evolution Neural Networks. We also work on methods for dose-response curve modeling using evolutionary algorithms and methods for variable selection and dimensionality reduction in genome-wide association studies. We work on performing association mapping to detect genes that are associated with differential response to pharmaceutical agent exposure. We study clinical trials and in cell line models of response. We also collaborate with several investigators to understand complex human diseases, compare disease etiology across species, and perform gene mapping for a range of common, complex diseases.

As chief of the NIEHS Biostatistics & Computational Biology Branch, I oversee a dynamic and diverse staff that is involved in biostatistical and computational methods development, software development, study design, and collaborative real data applications.


Motsinger-Reif obtained her Ph.D. in Human Genetics and a MS in Applied Statistics from Vanderbilt University. She was faculty member at North Carolina State University from 2007 to 2018. In December 2018, she joined NIEHS as chief of the Biostatistics & Computational Biology Branch.

Selected Publications

  1. Marvel S, House J, Wheeler M, Song K, Zhou Y, Wright F, Chiu W, Rusyn I, Motsinger-Reif A, Reif DM. The COVID-19 Pandemic Vulnerability Index (PVI) Dashboard: monitoring county level vulnerability. medRxiv. 2020.

  2. Akhtari FS, Havener TM, Fukudo M, Jack JR, McLeod HL, Wiltshire T, Motsinger-Reif AA. The influence of Neanderthal alleles on cytotoxic response. PeerJ. 2018;6:e5691.

  3. Jack J, Small GW, Brown CC, Havener TM, McLeod HL, Motsinger-Reif AA, Richards KL. Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance. Pharmacogenomics J. 2018;18(3):467-473.

  4. Rotroff DM, Pijut SS, Marvel SW, Jack JR, Havener TM, Pujol A, Schluter A, Graf GA, Ginsberg HN, Shah HS, Gao H, Morieri ML, Doria A, Mychaleckyi JC, McLeod HL, Buse JB, Wagner MJ, Motsinger-Reif AA, ACCORD/ACCORDion Investigators.. Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 Diabetes. Clin Pharmacol Ther. 2018;103(4):712-721.

  5. Rotroff DM, Yee SW, Zhou K, Marvel SW, Shah HS, Jack JR, Havener TM, Hedderson MM, Kubo M, Herman MA, Gao H, Mychaleckyi JC, McLeod HL, Doria A, Giacomini KM, Pearson ER, Wagner MJ, Buse JB, Motsinger-Reif AA, MetGen Investigators., ACCORD/ACCORDion Investigators.. Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes. 2018;67(7):1428-1440.

This page was last updated on August 27th, 2019